UFP Technologies, Inc. (UFPT) Stock Price & How to Invest

UFP Technologies, Inc. is a contract development and manufacturing organization headquartered in Newburyport, Massachusetts, incorporated in Delaware in 1993 and listed on Nasdaq as UFPT. It engineers and manufactures single-use and single-patient medical devices, components and packaging that customers sell under their own labels: protective drapes for robotic surgery, surgical and endoscopic disposables, advanced wound care and infection prevention products, packaging for orthopedic implants, cardiac implant components and catheter dispenser coils. The work runs through die cutting, molding, thermoforming, welding and lamination under trademarks including UFP MEDTECH, FLEXSHIELD and BIOSHELL. The company had ~4,846 full-time employees as of January 2026, up from ~4,146 a year earlier, across plants in the United States, Puerto Rico, the Dominican Republic, Mexico, Ireland and Costa Rica; nineteen sites are ISO 13485 certified and thirteen are FDA registered. Medical customers supplied ~92.1% of 2025 net sales.

The financial picture is a steady grower that the market has repriced sharply in both directions. Full-year 2025 revenue reached ~$603 million, up ~19.5% from ~$504 million in 2024, and the trailing twelve months through June 2026 stand at ~$632 million with ~$72 million of net income and diluted earnings per share of ~$9.25. The June 2026 quarter was a record on all three measures: revenue of ~$174.0 million (up ~15.1%, ~12.4% organic), net income of ~$20.9 million, and GAAP earnings per share of ~$2.68 against adjusted earnings per share of ~$2.92. Gross margin improved to ~29.3% from ~28.8%. At roughly ~33 times trailing earnings and a ~$2.36 billion market value, after a twelve-month band of about ~$174 to ~$339, the central question is whether a business with ~46% of sales in two accounts and a large production transfer still working through its costs deserves that multiple.

Customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier. A cybersecurity incident detected on or about February 14, 2026 disrupted systems including billing and label making, and certain company data appears to have been stolen or destroyed; UFP expects most direct costs to be recovered through insurance, but has disclosed that litigation, regulatory investigations or enforcement actions remain possible outcomes. The Dominican Republic facilities are described in the filings as crucial to operations, and the company specifically names civil unrest in nearby Haiti and natural disaster exposure among its concerns. Cash conversion was weak in the first half of 2026, with ~$18.8 million of operating cash flow against ~$38.3 million of net income as receivables rose ~$30.5 million. The stock also carries roughly ~33 times trailing earnings after a twelve-month range of about ~$174 to ~$339, so the multiple has historically moved a great deal on modest changes in the growth rate.

We give no verdict on UFP Technologies, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Intuitive Surgical contract, now written through 2029. Intuitive Surgical SARL is named in the filings as UFP's largest customer, and in February 2026 the two signed Amendment No.

The case against. Customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier.

Read the full bull and bear case on UFPT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see UFP Technologies, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$632M
• FY2025 revenue: ~$603M (up ~19.5% YoY)
• Q2 2026 revenue: ~$174.0M (up ~15.1% YoY, ~12.4% organic)
• Net income (TTM): ~$72M, diluted EPS ~$9.25
• Gross margin (Q2 2026): ~29.3%, up from ~28.8%
• Long-term debt: ~$117M at ~5.0% weighted average rate

At about ~$304 per share on ~7.75 million shares outstanding, UFPT carries a market value near ~$2.36 billion, which is roughly ~33 times trailing earnings and roughly ~3.7 times trailing revenue. That is a premium to most contract manufacturers, reflecting the medical mix, the ~29% gross margin and a multi-year record of double-digit growth. The balance sheet is light, with ~$117 million of long-term debt against a ~$275 million facility maturing in June 2029.

Other names that sit close to UFPT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get UFPT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so UFPT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where UFPT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

UFPT is a profitable medtech outsourcing business compounding through acquisition and offshore capacity, with two very large customers sitting at the center of both the growth and the risk.

Whether UFPT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is UFPT a buy or a sell?, and where the stock could go from here in the UFPT stock forecast.

For income investors, whether UFPT pays a dividend and how the payout looks is covered in does UFPT pay a dividend? And to weigh UFPT against a peer, read the full side-by-side comparisons: UFPT vs HNGE and UFPT vs BMY.